Zobrazeno 1 - 10 of 206 pro vyhledávání: '"JA Iribarren"'
1
Tenofovir Disoproxil Fumarate and severity of COVID-19 in people with HIV infection
Autor: J Del Amo, R Polo, S Moreno, E Martínez, A Cabello, JA Iribarren, A Curran, J Macías, M Montero, C Dueñas, AI Mariño, S Pérez de la Cámara, A Díaz, JR Arribas, I Jarrín, MA Hernán
BackgroundEffective, safe, and affordable antivirals are needed for COVID-19. Tenofovir has not been studied in randomized trials despite evidence consistent with its effectiveness against COVID-19.MethodsWe studied HIV-positive individuals on antire
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd6ba68c2c5946d48a74c499dcb1af7b
https://doi.org/10.1101/2021.11.11.21266189
Zobrazit plný text záznamu
2
1ISG-005 A cost-effective strategy: switching from one to two tablets, in a once-daily regimen in HIV patients
Autor: J Landa Alberdi, L Lombera Saez, MP Carmona Oyaga, LM Mendarte Barrenechea, MJ Gayan Lera, G Lopez Arzoz, Mauelon Echeverria, A Zurutuza Lopez, MP Bachiller Cacho, JA Iribarren Loyarte
Publikováno v: Section 1: Introductory Statements and Governance.
Background Following a request by the Central Management Organisation of our Health System (HS), a decision was made to change from a patented drug of three active principals, emtricitabine/tenofovir-disopropilo/rilpivirine (FTC/TDF/RPV) to two drugs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84b0c6339a4d52742b097d5a02441d52
https://doi.org/10.1136/ejhpharm-2019-eahpconf.5
Zobrazit plný text záznamu
3
Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort
Autor: I, Suárez-García, P, Sobrino-Vegas, A, Tejada, P, Viciana, Ma, Ribas, Ja, Iribarren, M, Díaz Menéndez, M, Rivero, P, Arazo, J, Del Amo, S, Moreno, Mónica, Trastoy
Publikováno v: HIV medicine. 15(2)
The aim of the study was to assess the adequacy of initial antiretroviral therapy (ART), in terms of its timing and the choice of regimens, according to the Spanish national treatment guidelines [Spanish AIDS Study Group-National Plan for AIDS (GeSID
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::81bb9d454bf31c84c738b7529b2d68a1
https://pubmed.ncbi.nlm.nih.gov/24007468
Zobrazit plný text záznamu
7
CPC-014 Analysis of Antiretroviral Therapy in Adult HIV Patients in a Tertiary Hospital
Autor: A Aranguren Redondo, B. Odriozola Cincunegui, JA Iribarren Loyarte, G Lopez Arzoz, O Valbuena Pascual, MP Bachiller Cacho, P Carmona Oyaga, P Pascual Gonzalez, MJ Gayan Lera, K Andueza Granados
Publikováno v: European Journal of Hospital Pharmacy. 20:A170.2-A170
Background Current guidelines (GESIDA/PNS-2012) for antiretroviral therapy (ART) in adults recommend the combination of 3 drugs for the treatment of chronic HIV infection. Purpose To analyse the ART in adult HIV- infected patients monitored in our ho
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::673b8dbb0d7af783c6fbe7dc76db9e1b
https://doi.org/10.1136/ejhpharm-2013-000276.471
Zobrazit plný text záznamu
8
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
Autor: D Nieves, O de la Calle, I Pérez-Escolano, JA Iribarren, M Brosa, A Rivero, L García-Bujalance
Publikováno v: Journal of the International AIDS Society. 11:P314
Purpose of the study The nucleoside reverse transcriptase inhibitor abacavir is prescribed, in combination with other drugs, for the treatment of HIV-1. Roughly 4–8% of patients receiving abacavir experience a hypersensitivity reaction (HSR), which
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::801af631d4410bd4c978544a8ad00526
https://doi.org/10.1186/1758-2652-11-s1-p314
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje